ZYBERNO
Stock Report
Updated Sep 1, 2026

DERMATA THERAPEUTICS, INC. (DRMA)

Healthcare • NASDAQ

$1.27

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
18.0/100
POOR BUSINESS
DERMATA THERAPEUTICS, INC. (DRMA) scores 18/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-166.7%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-710.4%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

DERMATA THERAPEUTICS, INC. (DRMA) stock report — Zyberno Score 18/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:1.27
Market Cap:$5.11M

Valuation Multiples (2)

P/B Ratio:1.46x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$695.36K

Price Action & Momentum (3)

Momentum Percentile:2 / 100
% of 52-Week High:20.4%
B. Profitability Assessment

Return Metrics (5)

ROA:-130.1%
Reinvestment Rate:0.0%
Fundamental Growth Rate (g):0.0%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$497.95
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:2.81x
Quick Ratio:2.73x
Cash Ratio:2.41x

Leverage Analysis (3)

Debt To Equity Ttm:0.00x
Debt-to-Equity Ratio:0.00x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:3,323,023.00
Cash And Cash Equivalents:4,412,764.00
Long Term Debt:$0.00
Net Debt:-$4.41M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$8.60M

Bottom Line Performance (3)

-$8.37M
Income Before Tax:$0.00
Ebitda Ttm:-8,601,013.00

Operating Expenses (5)

Operating Expenses:8,601,013.00
R And D Expense:1,627,294.00
Sga Expense:6,973,719.00
Income Tax Expense:$950.00
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$5.32M
Current Assets:$5.16M
Ppe Net:129,367.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:1,833,079.00
Current Liabilities:1,833,079.00
Long Term Debt:$0.00
Short Term Debt:$0.00

Equity & Capital (3)

Equity:$3.49M
Retained Earnings:-$78.05M
Common Stock:250,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:149,734.00
Accounts Payable:1,119,718.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:41,780.00
C. Cash Flow Analysis

Operating Activities (2)

-$8.30M$0.00

Investment Activities (1)

Investing Cash Flow:$0.00

Financing Activities (3)

Financing Cash Flow:$1.90M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:12,167,852.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-7.27
-$7.27
Earnings Per Share Ttm:-$2.08

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$1.93

Book Value & Capital (2)

Book Value Per Share:$0.87
Cash Per Share:1.10

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:0.0%
Fundamental Growth Rate (g):0.0%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):-15.3%
C. Company Profile & Context

Corporate Information (6)

Symbol:DRMA
Company Name:DERMATA THERAPEUTICS, INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:4.02M
Shares Outstanding Basic:4.02M
Shares Outstanding Diluted:4.02M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 18:54:00 UTC
Data Timestamp:2026-08-22T05:18:51.972930
Scroll to Top